A novel CD44v6 targeting antibody fragment with improved tumor-to-blood ratio.

@article{Sandstrm2012ANC,
  title={A novel CD44v6 targeting antibody fragment with improved tumor-to-blood ratio.},
  author={Karl Sandstr{\"o}m and A K Haylock and Diana Spiegelberg and Fredrik R Qvarnstr{\"o}m and Kenneth Wester and Marika Nestor},
  journal={International journal of oncology},
  year={2012},
  volume={40 5},
  pages={1525-32}
}
The chimeric monoclonal antibody U36 (cMAb U36) recognizes the CD44v6 antigen. Its potential as a radioimmunotargeting agent, as well as its safety, has been shown in previous studies in head and neck cancer patients. However, intact MAbs have long circulation time in the blood and tumor targeting may also be hampered due to the slow and incomplete diffusion into solid tumors. In comparison, smaller monovalent Fab' and divalent F(ab')2… CONTINUE READING
9 Citations
36 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 36 references

PET of hypoxia with 89 Zr - labeled cG 250F ( ab ' ) 2 in head and neck tumors

  • JL Murray, MG Rosenblum, HZ Zhang
  • 2010

Similar Papers

Loading similar papers…